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on Inflammation in PatientsWith Uveitis
A Randomized Clinical Trial
S. R. Rathinam, MD, PhD; John A. Gonzales, MD; Radhika Thundikandy, MD; Anuradha Kanakath, MD; S. Bala Murugan, MD; R. Vedhanayaki, MD;
Lyndell L. Lim, MBBS, DMedSci; Eric B. Suhler, MD, MPH; Hassan A. Al-Dhibi, MD; Thuy Doan, MD, PhD; Jeremy D. Keenan, MD, MPH; MayaM. Rao, MPH;
Caleb D. Ebert, MPH; Hieu H. Nguyen, MS; Eric Kim, MA; Travis C. Porco, PhD, MPH; Nisha R. Acharya, MD, MS; for the FAST Research Group
IMPORTANCE Methotrexate andmycophenolate mofetil are commonly used
immunomodulatory therapies for achieving corticosteroid-sparing control of noninfectious
uveitis, but there is uncertainty about which drug is more effective.
OBJECTIVE To compare the effect of methotrexate andmycophenolate for achieving
corticosteroid-sparing control of noninfectious intermediate uveitis, posterior uveitis,
and panuveitis.
DESIGN, SETTING, AND PARTICIPANTS The First-line Antimetabolites as Steroid-sparing
Treatment (FAST) uveitis trial screened 265 adults with noninfectious uveitis requiring
corticosteroid-sparing immunosuppressive therapy from 9 referral eye centers in India, the
United States, Australia, Saudi Arabia, andMexico between August 22, 2013, and August 16,
2017. Follow-up ended on August 20, 2018.
INTERVENTIONS Patients were randomized to receive oral methotrexate, 25mgweekly
(n = 107), or oral mycophenolate mofetil, 3 g daily (n = 109).
MAIN OUTCOMES ANDMEASURES The primary outcomewas treatment success at 6months,
which was defined as having control of inflammation in both eyes, nomore than 7.5 mg
prednisone daily and less than or equal to 2 drops of prednisolone acetate 1%, and no
treatment failure due to safety or intolerability. Patients underwent follow-up to 12 months
while receiving the same treatment or switched to the other antimetabolite, depending on
their 6-month outcome.
RESULTS Among 216 patientswhowere randomized (median age, 38 years; 135 (62.5%)
women), 194 (89.8%) completed follow-up through6months. Treatment success occurred in
64 (66.7%) patients in themethotrexate group vs 56 (57.1%) in themycophenolate group
(difference, 9.5% [95%CI, −5.3% to 21.8%]; odds ratio [OR], 1.50 [95%CI, 0.81 to 2.81]; P = .20).
Among patientswith posterior uveitis or panuveitis, treatment successwas achieved in 58
(74.4%) in themethotrexate group vs 42 (55.3%) in themycophenolate group (difference, 19.1%
[95%CI, 3.6% to 30.6%]; OR, 2.35 [95%CI, 1.16 to 4.90]; P = .02); whereas among patientswith
intermediate uveitis treatment success occurred in 6 (33.3%) in themethotrexate group vs 14
(63.6%) in themycophenolate group (difference, −30.3% [95%CI, −51.6% to 1.1%]; OR, 0.29
[95%CI, 0.08 to 1.05]; P = .07; P for interaction = .004). Elevated liver enzymeswere themost
commonnonserious laboratory adverse event, occurring in 14 patients (13.0%) in the
methotrexate group and8patients (7.4%) in themycophenolate group.
CONCLUSIONS AND RELEVANCE Among adults with noninfectious uveitis, the use of
mycophenolate mofetil compared with methotrexate as first-line corticosteroid-sparing
treatment did not result in superior control of inflammation. Further research is needed to
determine if either drug is more effective based on the anatomical subtype of uveitis.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01829295
JAMA. 2019;322(10):936-945. doi:10.1001/jama.2019.12618
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U veitis, a group of diseases characterized by sight-threatening intraocular inflammation, is the fifthmostcommoncauseof severevision loss inhigh-incomena-
tions and was estimated to be responsible for 10% to 15% of
all blindness cases in the United States in epidemiology stud-
ies conducted in the 1990s.1,2 Uveitis can be associatedwith a
systemicdiseaseorbeeye limitedandaffectspeopleofall ages,
whichmay lead to greater years of vision loss than other age-
related diseases.3
The standard first-line treatment for noninfectious uveitis
is corticosteroids (topical, systemic, injections, and implants).
However, corticosteroid therapy has local and systemic ad-
verseeffectsmakingits long-termuseundesirable.4Timelyman-
agement of uveitis is critical to prevent permanent vision loss,
andmultidisciplinary collaboration is often required given the
need for corticosteroid-sparing immunosuppression.
The antimetabolites methotrexate and mycophenolate
mofetilarecommonlyusedasinitialcorticosteroid-sparingtreat-
ments foruveitisbeforeprogressingtobiologic therapies,which
aremoreexpensiveandhaverisks for seriousadverseeffects.5-7
Noncomparativeretrospectivecaseseriesgenerallysuggest that
mycophenolatemofetilmaybemoreeffectiveand tolerable for
patientswithuveitis, but there is a lack of evidence comparing
the effectiveness of these treatments.5,8-12
Theprimaryobjectiveofthisstudywastocomparetherela-
tiveeffectivenessofmethotrexateandmycophenolatemofetil
for achieving corticosteroid-sparing control of noninfectious
intermediate uveitis, posterior uveitis, and panuveitis.
Methods
Study Design and Eligibility
The First-line Antimetabolites as Steroid-sparing Treatment
(FAST)uveitis trialwasaNationalEye Institute–supportedmul-
ticenter, randomized,parallel, observer-maskedclinical trial at
9 referral eye care centers in India, theUnitedStates,Australia,
SaudiArabia,andMexico.Tobeeligible for thetrial,patientshad
tobe16yearsofageorolder,haveactivenoninfectious interme-
diateuveitis,posterioruveitis,orpanuveitis inat least 1eye,and
haveajustificationforstartingcorticosteroid-sparingtherapy(see
eBox in Supplement 1 for complete eligibility criteria). Institu-
tional reviewboardapprovalwasobtainedatall centers.All pa-
tients provided written informed consent. Race and ethnicity
wereself-reportedbypatientsbasedonfixedcategories tocom-
plywithNational InstitutesofHealthandUSFoodandDrugAd-
ministrationguidelines.13,14All researchproceduresadhered to
the tenets of the Declaration of Helsinki. The studywasmoni-
toredbyanindependentdataandsafetymonitoringcommittee.
The trial protocol and statistical analysis plan are available on-
line (Supplement 2 and Supplement 3).
Randomization
Patients were randomized (1:1 allocation ratio) to methotrex-
ate or mycophenolate mofetil using permutated blocks of
size 4 and 6 and stratified by study site, and allocation was
concealed until after enrollment. The principal statistician
generated the random allocation sequence using the statisti-
cal softwareR(RProject forStatisticalComputing,version2.12).
After investigators confirmed eligibility, the study coordina-
tor obtained the treatment assignment through theonlineRe-
search Electronic Data Capture (REDCap) system.15
Study Timeline, Masking, and Assessments
Allpatients completedstudyvisits atbaseline,2weeks, andev-
ery4weeksupto6months.Schedulingofstudyvisitswasbased
on the enrollment date. The primary outcome was measured
at 6months (Figure 1). Patientswith treatment success contin-
ued taking their randomizedmedication for another6months.
If treatment failed, patients switched to the other antimetabo-
lite plus 6-month follow-up. Personnel responsible for out-
comemeasurements (ophthalmologists, visual acuityexamin-
ers,andopticalcoherencetomographyoperators)weremasked,
includingafter switchingmedications. Studycoordinators and
patients were notmasked to themedication assignment.
Ophthalmologists, masked to patients’ assigned treat-
ment group, measured anterior chamber cells according to
the Standardization of Uveitis Nomenclature (SUN) guide-
lines. Vitreous haze was assessed by the standardized
National Eye Institute scoring system. Retinal and choroidal
lesions were assessed by clinical examination and imaging
studies. Visual acuity examiners (also masked to patients’
treatment group) measured best spectacle-corrected visual
acuity using an ETDRS letter or tumbling “E” logarithm of the
minimum angle of resolution chart at 4 m. Macular thickness
was assessed using optical coherence tomography. Macular
edema thresholds were greater than or equal to 315 μm for
Spectralis (Heidelberg Engineering) and greater than or equal
to 300 μm for Cirrus (Carl Zeiss Meditec).
Treatment
The University of California San Francisco pharmacy pro-
vided study drugs for all sites. Patients were randomized and
started treatmentwithan initial dose for 2weeks toensure tol-
erability (15mgweeklyoralmethotrexateor500mgtwicedaily
oralmycophenolatemofetil).Thedosewas increasedtoamain-
tenance level for the remainder of the trial: 25 mg weekly for
the oral methotrexate group and 1.5 g twice daily for the oral
mycophenolate mofetil group. If patients experienced intol-
erable symptomsor adverse events, dose of the trial drugwas
Key Points
Question Is methotrexate or mycophenolate mofetil more
effective as first-line immunosuppressive treatment for patients
with noninfectious intermediate uveitis, posterior uveitis,
or panuveitis requiring corticosteroid-sparing therapy?
Findings In this randomized clinical trial of 216 patients with
active noninfectious intermediate uveitis, posterior uveitis, and
panuveitis, 66.7% of patients in themethotrexate group achieved
corticosteroid-sparing control of inflammation compared with
57.1% in themycophenolate group, a difference that was not
statistically significant.
Meaning Mycophenolate mofetil was not more effective than
methotrexate in treating noninfectious uveitis.
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reduced (see eTable 3 in Supplement 1 for dosing informa-
tion) at thediscretionof the investigator;maskingof studyper-
sonnel ascertaining outcomeswas preserved.Monthly calen-
dars were provided to patients to record any missed doses.
Patients were prescribed oral prednisone (1 mg/kg or 60 mg
daily [whicheverwas less]) at enrollment and tapered accord-
ing to SUN guidelines, with a goal of tapering and holding at
7.5 mg daily prednisone at month 6.16 Following the primary
end point, prednisone could be tapered off. If needed, pa-
tients took topical corticosteroids but were instructed to ta-
per to 2 drops or less per day of prednisolone acetate 1% or
equivalent bymonth6. Periocular and intravitreal corticoste-
roid injections could be administeredwithin the first 90 days
after randomization formacularedemaif investigatorsdeemed
additional treatment was needed; other injections were con-
sidered protocol deviations.
Outcomes
Theprimaryoutcomewastreatmentsuccessat thepatient level,
defined by achieving corticosteroid-sparing control of inflam-
mation in both eyes (or single eye if other eyewasunevaluable
at baseline) at themonth 6 visit, defined by the following:
(1) less than or equal to 0.5+ anterior chamber cells by
SUN criteria,16 less than or equal to 0.5+ vitreous haze clinical
grading using the NEI scale,16 and no active retinal or choroi-
dal lesions; and (2) no more than 7.5 mg of oral prednisone
daily and less than or equal to 2 drops of prednisolone
acetate 1% (or equivalent) per day; and (3) no declaration of
treatment failure due to intolerability or safety concerns.
Treatment failuredue toefficacywasdeclared if either cri-
terion 1 or 2 (listed in the previous paragraph) was not met at
6 months or declared earlier if a patient had persistent wors-
ening inflammation. Treatment failure could be declared due
to safety (eg, if a patient had an abnormal laboratory result
meeting the serious adverse event threshold) or intolerability
(eg, if a patient was unable or unwilling to continue medica-
tion due to adverse effects) at 6months. The same definition
of treatment success was applied to 12-month outcomes.
Prespecified secondaryoutcomes included treatment suc-
cessat6monthsbyanatomicalsubtypeofuveitis,byenrollment
Figure 1. Patient Flow From Screening to 12-Month Analysis
265 Patients assessed for eligibility
49 Excluded
31 Unwilling to participate
1 Planning pregnancy
11 Unable to attend monthly visits
6 Unwilling to abstain from alcohol
12-Month secondary analysis
60 Continued methotrexate and
were included in the 12-month
secondary analysis (118 eyes
with uveitis)
12-Month secondary analysis
29 Switched to methotrexate and
were included in the 12-month
secondary analysis (57 eyes
with uveitis)
12-Month secondary analysis
20 Switched to mycophenolate
mofetil and were included in
the 12-month secondary
analysis (36 eyes with uveitis)
12-Month secondary analysis
54 Continued mycophenolate and
were included in the 12-month
secondary analysis (103 eyes
with uveitis)
216 Patients randomized
(407 eyes with uveitis)
107 Randomized to receive methotrexate
107 Received allocated intervention
(206 eyes with uveitis)
109 Randomized to receive mycophenolate mofetil
108 Received allocated intervention
(201 eyes with uveitis)a
6-Month follow-up
9 Lost to follow-up prior to 6-month visit
(1 death) (18 eyes with uveitis)
2 Missed 6-month visit (3 eyes with uveitis)
6-Month primary analysis
96 Included in the primary analysis
(185 eyes with uveitis)
6-Month follow-up
10 Lost to follow-up prior to 6-month visit
(19 eyes with uveitis)
1 Missed 6-month visit (1 eye with uveitis)
6-Month primary analysis
98 Included in the primary analysis
(181 eyes with uveitis)
12-Month follow-up
3 Not eligible to continue in study due to safety
reasons (6 eyes with uveitis)
2 Withdrew from the study (4 eyes with uveitis)
9 Unwilling to switch to mycophenolate mofetil
(17 eyes with uveitis)
2 Lost prior to 12-month visit (4 eyes with uveitis)
12-Month follow-up
2 Not eligible to continue in study due
to safety reasons (3 eyes with uveitis)
2 Withdrew from the study (3 eyes with uveitis)
11 Unwilling to switch to methotrexate
(15 eyes with uveitis)
a One patient did not receive mycophenolate mofetil due to amedical contraindication discovered postrandomization.
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site or country, treatment success at 12months inpatientswho
continued their randomized antimetabolite and patients who
switched to theother antimetabolite, visual acuity, andcentral
subfieldmacular thickness at 6months. Additional secondary
outcomesnot reported in this articlewere time to control of in-
flammation; sustained treatment success; treatment success in
theVogt-Koyanagi-Haradasubgroup;qualityoflifebythe36-Item
ShortFormSurvey(SF-36),theNationalEyeInstituteVisualFunc-
tion Questionnaire (NEI-VFQ-25), and the Indian Vision Func-
tionQuestionnaire (IND-VFQ); andchanges inspecificmanifes-
tations of uveitis, such as anterior chamber cell inflammation,
vitreous haze, retinal or choroidal lesions, and vasculitis.
Statistical Analyses
Enrollmentof216patientswasestimatedtoprovide80%power
todetectaclinicallymeaningful absolutedifferenceofapproxi-
mately 20% in treatment success between the methotrexate
group (40%) and themycophenolatemofetil group (60%), as-
suming 10% loss to follow-up and a 2-tailed α of 0.05. This risk
difference in favorofmycophenolatemofetilwas supportedby
retrospective studies.9,11,17 The prespecified primary outcome
analysiswas amixed-effects logistic regression toestimate the
association between treatment group as the fixed effect and
treatment success at 6months. Site was included as a random
effect. This outcome was evaluated at the patient level. Odds
ratios (ORs) and their 95%CIswere calculated from the regres-
sion. Equivalent absolute risk differences and 95%CIs are also
reported. All patients with a 6-month visit or who were de-
clared as having early treatment failurewere analyzed accord-
ingtotheir randomizationgroup.Patientsmissingaprimaryout-
come visit were not included in the primary analysis. As a
sensitivityanalysis,multiple imputationwasusedto infermiss-
ingprimaryoutcomedata.The same logisticmodelused in the
primary outcome analysis was applied at 12months. A nonin-
feriorityanalysiswitha2-sidedsignificance levelof .05waspre-
specifiedtoevaluatewhethermethotrexate isnoninferiortomy-
cophenolate mofetil for achieving treatment success at 6
months,withanabsolutemargin in riskdifferenceof 10%.The
noninferiority margin of 10% was based on investigator con-
sensus and would likely exclude the effect of placebo
(Supplement 3).18 Sensitivity analyses were preplanned to ex-
amineforheterogeneity intreatmenteffectacrosssiteandcoun-
try. Because of the potential type I error due to multiple com-
parisons, findings for analyses of secondary endpoints should
be interpreted as exploratory.
Retrospective studies and clinical trials have demon-
stratedposterioruveitis andpanuveitis tobeamoresevereand
complicateduveitis subtype to treat.19-21Wehypothesized that
theremaybeadifference intreatmenteffectbyanatomicaluve-
itis subtype and thus, prespecified a subgroup analysis (inter-
mediate uveitis vs posterior uveitis and panuveitis) of treat-
ment success. The primary outcome logistic regression was
used for this subanalysis.
Other secondary outcomeswere also examined using the
primary outcome logistic regression model. Eye-level out-
comes, including change in visual acuity and central subfield
macular thickness,were comparedbetween treatment groups
with a linear regression model clustering on patient. Only
uveitic eyes at enrollment were included in eye-level analy-
ses. Patients with bilateral uveitis had both eyes included.
Thefrequencyandproportionofpatientsexperiencingnon-
serious and serious ocular, laboratory, and systemic adverse
eventswerecalculatedforeachgroup.Dosereductionsandpro-
tocol deviations were compared between treatment groups
usingaFisherexact test.Misseddoseswerecomparedbygroup
using a Welch t test. Statistical significance was declared at
2-sided P value of less than .05. Permutation CIs were calcu-
lated for the primary outcome with permuted P values based
on the randomized treatment assignment.Datawere analyzed
using R version 3.51 (R Project for Statistical Computing).
Results
TwohundredsixteenpatientswererandomizedbetweenAugust
2013 andAugust 2017 (107 patients to themethotrexate group
and109patients to themycophenolatemofetil group). Sixeyes
wereunevaluabledue tophthisis and 19 eyeshadnohistory of
uveitis, leaving206uveitic eyes in themethotrexategroupand
201 uveitic eyes in the mycophenolate mofetil group. Patient
follow-upwas completed inAugust 2018, and 194patients (96
in themethotrexategroupand98 inthemycophenolatemofetil
group) had complete information for the primary outcome
(Figure 1); 22 patients (10.2%)were lost to follow-up.
Table 1 shows the baseline demographic and clinical char-
acteristics for both groups. Most patients had bilateral uveitis
(92.5% in themethotrexate group and 84.4% in themycophe-
nolate mofetil group). Forty-six patients (21.3%) had interme-
diate uveitis only or anterior uveitis and intermediate uveitis,
and 170patients (78.7%)hadposterior uveitis or panuveitis. In
the 180 days prior to enrollment, the highest oral prednisone
(or equivalent) dose administered was amedian 50mg (inter-
quartile range [IQR], 40-60mg) in themethotrexategroupand
50mg(IQR,40-75mg) inthemycophenolatemofetil group.The
initial corticosteroid dose at enrollment for each group was a
median of 50 mg (0.9 mg/kg [IQR, 40-60 mg]). Fifteen pa-
tients (6.9%) had previously attempted immunosuppressive
therapymore than 12months prior to enrollment.
Six-Month Primary Outcome Analysis
At the 6-month primary end point, 120 patientsmet the defi-
nition of treatment success (Table 2). In the primary analysis,
treatment success was achieved in 64 patients in the metho-
trexate group vs 56 patients in the mycophenolate mofetil
group (66.7% vs 57.1%; difference, 9.5% [95% CI, −5.3% to
21.8%]; odds ratio [OR], 1.50 [95% CI, 0.81 to 2.81]; P = .20).
Reasons for treatment failure are listed in Table 2.
Prespecified 6-Month Secondary Outcomes
For thenoninferiority analysis, the lower boundof the95%CI
of the risk difference derived from the primary analysis was
−5.3%andexcluded theprespecified 10%noninferioritymar-
gin.Thisprovidesevidenceofmethotrexatenoninferioritywith
respect to mycophenolate mofetil.
Treatment success in patients with posterior uveitis and
panuveitis was greater in the methotrexate group vs in the
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mycophenolatemofetilgroup(74.4%vs55.3%;difference,19.1%
[95%CI,3.6%to30.6%];OR,2.35 [95%CI, 1.16 to4.90];P = .02;
anatomical subtypeandtreatment interaction,P = .004).Treat-
ment successwasnot significantlydifferentbetweengroups in
patients with intermediate uveitis (33.3% in themethotrexate
groupvs63.6%inthemycophenolatemofetil group;difference,
Table 1. Baseline Characteristics of Patients by Treatment Assignment
Patient-Level Characteristicsa
Methotrexate
(n = 107)
Mycophenolate Mofetil
(n = 109)
Age, median (IQR), y 36 (26-50) 41 (31-51)
Female sex 75 (70.1) 60 (55.0)
Male sex 32 (29.9) 49 (45.0)
Hispanic ethnicity 5 (4.7) 7 (6.4)
Raceb
Indian subcontinent 70 (65.4) 69 (63.3)
White 25 (23.4) 22 (20.2)
Asian 5 (4.7) 6 (5.5)
Middle Eastern 5 (4.7) 5 (4.6)
Black 3 (2.8) 6 (5.5)
Native American 2 (1.9) 1 (0.9)
Pacific Islander 1 (0.9) 3 (2.8)
Uveitis diagnosis
Vogt-Koyanagi-Harada disease 49 (45.8) 44 (40.4)
Undifferentiated 22 (20.6) 20 (18.3)
Retinal vasculitis 8 (7.5) 13 (11.9)
Sarcoidosis 7 (6.5) 8 (7.3)
Sympathetic ophthalmia 3 (2.8) 8 (7.3)
Behçet disease 5 (4.7) 3 (2.8)
Pars planitis 2 (1.9) 5 (4.6)
Birdshot chorioretinopathy 3 (2.8) 3 (2.8)
Other 8 (7.5) 5 (4.6)
Bilateral uveitis 99 (92.5) 92 (84.4)
Duration of uveitis, median (IQR), d 135 (20-550) 122 (21-783)
Anatomic location, based on entire uveitis historyc
Panuveitis 60 (56.1) 61 (56.0)
Posterior uveitis 24 (22.4) 25 (22.9)
Anterior uveitis and intermediate uveitis 15 (14.0) 14 (12.8)
Intermediate uveitis 8 (7.5) 9 (8.3)
Systemic corticosteroid use
Maximum dose of oral prednisone
or equivalent in past 180 days, median (IQR), mgd 50 (40-60) 50 (40-75)
Oral prednisone at baseline, median (IQR), mg 50 (40-60) 50 (40-60)
Prior treatment with immunosuppressive therapy 8 (7.5) 7 (6.4)
Eye-Level Characteristics Methotrexate(n = 206 eyes)
Mycophenolate Mofetil
(n = 201 eyes)
Inflammation at baseline
Anterior chamber cells 205 (99.5) 201 (100.0)
0 84 (41.0) 87 (43.3)
0.5+ 53 (25.9) 47 (23.4)
1+ 46 (22.4) 47 (23.4)
≥2+ 22 (10.7) 20 (10.0)
Anterior vitreous cells 202 (98.1) 200 (99.5)
0 34 (16.8) 33 (16.5)
0.5+ 40 (19.8) 48 (24.0)
1+ 52 (25.7) 51 (25.5)
≥2+ 76 (37.6) 68 (34.0)
Vitreous haze 202 (98.1) 200 (99.5)
0 85 (42.1) 97 (48.5)
0.5+ 30 (14.9) 34 (17.0)
1+ 50 (24.8) 30 (15.0)
≥2+ 37 (18.3) 39 (19.5)
Active retinal or choroidal lesions, n/N (%) 125/202 (61.9) 119/200 (59.5)
Macular edemae 42 (20.4) 55 (27.3)
Central subfield thickness, median (IQR), μmf 359.0 (331.5-449.5) 342.0 (316.0-398.5)
LogMAR visual acuity, median (IQR)g 0.28 (0.03-0.52) 0.30 (0.08-0.60)
Abbreviations: IQR, interquartile
range; logMAR, logarithm of the
minimum angle of resolution.
a Values are reported as No. (%)
unless otherwise indicated.
b Seven patients listed being of more
than 1 racial heritage.
c Anatomic location was assessed
given all medical records available.
d Corticosteroids in the past 180 days
included oral, subcutaneous, and
intravenous, and were adjusted to
equivalent calculations of oral
prednisone.
e Macular edema excluded patients
with Vogt-Koyanagi-Harada disease
who had a serious retinal
detachment.
f Characteristic was reported in
patients with macular edema.
g Indicates best-corrected visual
acuity of uveitic eyes only.
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−30.3%[95%CI,−51.6%to1.1%];OR,0.29[95%CI,0.08to1.05];
P = .07).
There was no significant difference in the change in vi-
sual acuity between treatment groups (0.2 lines greater in the
mycophenolatemofetil group [95%CI, 1.7 lines less to2.0 lines
greater]; P = .83). There was also no significant difference in
thechange incentral subfieldmacular thicknessbetweentreat-
ment groups at 6months (2.4 μmgreater in themethotrexate
group [95%CI, −78.0μmto82.8μm];P = .95). Best spectacle-
correctedvisual acuity improvedbyamedianof 1.0 line in the
methotrexate group (IQR, 0.0 to 3.2 lines), and by a median
of 1.2 lines in the mycophenolate mofetil group (IQR, 0.0 to
3.1 lines; Table 2). The central subfieldmacular thickness de-
creasedbyamedianof 26μm in themethotrexate group (IQR,
−89 to 5) and 14μm in themycophenolatemofetil group (IQR,
−80 to3.25). Sevenpatients (7 eyes) in themethotrexategroup
and5patients (5eyes) in themycophenolatemofetil groupwere
treated per protocol for macular edema with a corticosteroid
injection within 90 days of randomization. Four patients (7
eyes) in themethotrexate group and 4 patients (4 eyes) in the
mycophenolatemofetil group received a corticosteroid injec-
tion thatwas considered a protocol deviation (>90 days post-
randomization).
The mean (SD) proportion of expected doses missed was
4.6% (1.0%) for patients receiving weekly methotrexate and
4.3%(0.5%) forpatients receivingdailymycophenolatemofetil
(P = .87). A sensitivity analysis of the primary model that in-
cluded only patientswhomissed less than 20%of their doses
did not substantially change the result. Twenty-one (19.6%)
patients in themethotrexate group and 15 (13.8%) patients in
the mycophenolate mofetil group reduced their study medi-
cation (P = .27), mostly due to intolerability.
Subgroup and Sensitivity Analyses of 6-Month Outcomes
In sensitivity analyses of the primary outcome assessing the
effect of clinic location, interaction tests in all models were
foundnot tobe statistically significant, indicatinga lackof evi-
dence of heterogeneity (India and treatment group, P = .15;
country [United States andMexico combined] and treatment
group, P = .45; eTable 7 in Supplement 1). Treatment success
Table 2. Six-Month Results From a Randomized Clinical Trial ComparingMethotrexate andMycophenolateMofetil for Noninfectious Uveitis
Patient-Level Characteristics
Methotrexate
(n = 96)
Mycophenolate Mofetil
(n = 98)a
Absolute Risk Difference
for Treatment Success,
% (95% CI)
OR Estimate
for Treatment Success
(95% CI)b P Value
Primary Analysis
Treatment success, No. (%)c 64 (66.7) 56 (57.1) 9.5 (−5.3 to 21.8) 1.50 (0.81 to 2.81) .20
Treatment failure, No. (%) 32 (33) 42 (43)
Secondary Analyses
Reason for treatment failure, no./No. (%)
Efficacyc 26/32 (81) 38/42 (90)
.55Intolerabilityd 3/32 (9) 2/42 (5)
Safetye 3/32 (9) 2/42 (5)
Treatment success by anatomical location, no./No. (%)
Anterior uveitis and intermediate uveitis/
intermediate uveitis only 6/18 (33.3) 14/22 (63.6) −30.3 (−51.6 to 1.1) 0.29 (0.08 to 1.05) .07
f
Posterior uveitis/panuveitis 58/78 (74.4) 42/76 (55.3) 19.1 (3.6 to 30.6) 2.35 (1.16 to 4.90) .02f
Treatment success at 12 mo, no./No. (%)
Continued on randomized antimetaboliteg 48/60 (80) 40/54 (74) 5.9 (−12.2 to 17.0) 1.40 (0.57 to 3.56) .47
Switched to other antimetaboliteh 20/29 (69) 7/20 (35) 34.2 (6.6 to 52.6) 4.17 (1.32 to 13.16) .02
Missed doses, mean (SD), %i 4.6 (1.0) 4.3 (0.5) .87
Eye-Level Characteristics Methotrexate(n = 185 eyes)
Mycophenolate Mofetil
(n = 181 eyes) P Value
k
Change in logMAR visual acuity, median (IQR)l −0.10 (−0.32 to 0.00) −0.12 (−0.31 to 0.00) .83
Reduction in central macular thickness,
median (IQR) [No.], μmm
−26.00
(−89.00 to 5.00) [42]
−14.00
(−80.00 to 3.25) [55] .95
Abbreviations: IQR, interquartile range; logMAR, logarithm of theminimum
angle of resolution; OR, odds ratio.
a Mycophenolate mofetil is the reference group.
b Logistic regression with treatment group as a fixed effect and study site
as a prespecified random effect.
c Treatment success was defined by achieving corticosteroid-sparing control
of inflammation in both eyes at themonth 6 visit.
d Treatment failure due to efficacy was defined by not achieving the treatment
success definition at month 6 or could be declared earlier if patient had
persistent worsening inflammation.
e Treatment failure due to intolerability was declared if a patient was unable
or unwilling to continuemedication due to adverse effects.
f Treatment failure due to safety was declared if a patient had an abnormal
laboratory result that met the serious adverse event threshold.
g Interaction between anatomical subtype and treatment group was significant
(P = .004).
hOf patientswho achieved treatment success at 6months, 60patients originally
randomized tomethotrexate and 54patients originally randomized to
mycophenolatemofetil continued on same antimetabolite through 12months.
i Ofpatientswhohadtreatmentfailureat6months,29patientsoriginallyrandomized
tomycophenolatemofetil switched tomethotrexate, and20patients originally
randomized tomethotrexate switched tomycophenolatemofetil.
j Indicates the number of missed doses over total expected doses throughout
a patient’s enrollment in the trial.
k P values computed from a linear mixed-effects model.
l Decrease indicates gain in visual acuity.
mIndicates eyes with macular edema excluding patients who had a serous
retinal detachment in the setting of Vogt-Koyanagi-Harada disease.
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was achieved in 22 patients in the methotrexate group vs 15
patients in themycophenolatemofetil group outside of India
(61.1% vs 38.5%; difference, 22.7% [95% CI, −2.6% to 43.1%];
OR, 2.5 [95% CI, 0.9 to 7.1]; P = .08; Figure 2).
A total of 22 of 216 patients (10.2%) missed the 6-month
primary outcome visit, 11 patients (50.0%) in the methotrex-
ategroupand11patients (50.0%) in themycophenolatemofetil
group. Sensitivity analysis of theprimaryoutcomeusingmul-
tiple imputation showed a similar result as the prespecified
analysiswith treatmentsuccessachieved in66patients (61.7%)
in the methotrexate group vs 59 patients (54.1%) in the my-
cophenolate mofetil group (difference, 7.6% [95% CI, −5.9%
to 19.1%]; OR, 1.4 [95% CI, 0.8 to 2.4]; P = .27).
Prespecified 12-Month Outcomes
Ofthe120patientswhoweredeclareda6-monthtreatmentsuc-
cess, 114 were followed up for an additional 6 months. Forty-
eight of 60 (80.0%)patients in themethotrexate group and40
of 54 (74.1%) patients in the mycophenolate mofetil group re-
mained a treatment success at 12 months, with the majority
(50.0%formethotrexateand55.0%formycophenolatemofetil)
discontinuing prednisone. Forty-nine of the 68 eligible pa-
tients inwhom treatment failed in the first 6months andwho
didnothavea serious laboratoryadverseevent switched to the
otherantimetabolite:20ofthe32(62.5%)patientsoriginallyran-
domized to methotrexate and 29 of the 42 (69.0%) originally
randomizedtomycophenolatemofetil.Therewasgreater treat-
ment success at 12months in themethotrexate group (69.0%)
in patients for whom mycophenolate mofetil had previously
failed vs patients in themycophenolatemofetil group (35.0%)
in whommethotrexate had failed (difference, 34.2% [95% CI,
6.6% to 52.6%]; OR, 4.2 [95% CI, 1.3 to 13.2]; P = .02).
Adverse Events
Table 3 shows the frequency andproportion of patients expe-
riencing nonserious or serious ocular, laboratory, and sys-
temic adverse events in each treatment group at 6 months.
Nonserious liver functiontestabnormalitiesoccurredmore fre-
quently inpatients receivingmethotrexate (14 [13.0%]) vsmy-
cophenolatemofetil (8 [7.4%]). Fatigueandheadachewere the
most common nonserious systemic adverse events (62 pa-
tients [57.9%] and 55 patients [51.4%]) in the methotrexate
group and also in the mycophenolate mofetil group (59 pa-
tients [54.6%] and 45 patients [41.7%]). Fourteen serious ad-
verse events occurred through the primary outcome with 5
deemeddrug-relatedby themaskedmedicalmonitor: 3 (2.8%)
in themethotrexate group and 2 (1.9%) in themycophenolate
mofetil group.All drug-related serious adverse eventswere el-
evated liver function tests. Twelve-month adverse events are
reported in eTables 8 and 9 in Supplement 1.
Discussion
Among adults with noninfectious uveitis, the use of myco-
phenolatemofetil comparedwithmethotrexateas first-linecor-
ticosteroid-sparing treatment did not result in superior con-
trol of inflammation.
Exploratoryhypothesis-generating secondaryanalysesas-
sessedtreatmentsuccessbyanatomical subgroupofuveitisand
at 12 months. Methotrexate was found to be more effective in
patients with posterior uveitis or panuveitis—the most severe
type of uveitis and the largest subgroup in this trial. Although
the results favoredmycophenolate mofetil, no significant dif-
ferencewasfoundintreatmentsuccesswiththeless-severesub-
group, intermediate uveitis. Ultimately, treatment success by
anatomical locationneeds tobeexplored further. Inboth treat-
mentgroups,mostpatientswhoachieved treatment success at
6 months remained a success through 12 months. Treatment
success in the 12-month analysis of patients switching treat-
mentafternotachievingcontrolwassuperior inpatientsswitch-
ing tomethotrexate after mycophenolatemofetil.
Overall, treatment failures due to intolerability and safety
were low.Abnormalities in liver function testsweremorecom-
mon with methotrexate treatment as expected.
Althoughthebiologicadalimumab isUSFoodandDrugAd-
ministration–approvedforuveitis,antimetabolitesarestill com-
monly used as initial corticosteroid-sparing therapy because
of their lower costs and fewer associated risks. Retrospective
noncomparative case series suggest that mycophenolate
mofetil may be more effective than methotrexate as a corti-
costeroid-sparing therapy foruveitis, but theheterogeneity in
Figure 2. Six-Month Primary Outcome and Sensitivity Analyses of the Primary Outcome
P Value
Favors
Mycophenolate
Favors
Methotrexate
1010.1
Odds Ratio of Treatment
Success (95% CI)
No./Total No. of Patients (%)
Methotrexate MycophenolateModel Analysis
Odds Ratio
of Treatment
Success (95% CI)
.2064/96 (67) 56/98 (57)1a Primary analysis 1.50 (0.81-2.81)
.9342/60 (70) 41/59 (69)2b Sites in Indiac 1.02 (0.44-2.37)
.0822/36 (61) 15/39 (38)3d Sites not in Indiac 2.51 (0.89-7.08)
.1761/90 (68) 54/94 (57)4e Per protocol 1.56 (0.84-2.96)
a Primary model is a logistic regression with treatment group as a fixed effect
and study site as a prespecified random effect (n = 194).
b Primary model with patients from sites in India only (n = 119).
c Treatment group and Indian site interaction termwas not significant (P =.15).
d Primary model with patients from sites not in India only (n = 75).
e Primarymodelwithpatientswhomissedlessthan20%ofstudymedication(n = 184).
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definitions of treatment success, patient populations, and
medication dosing in these reports make it difficult to com-
pare the effectiveness of methotrexate and mycophenolate
mofetil.5,11,12,17,21-26 Additionally, low doses of methotrexate
(≤15mg)wereroutinelyused in thesepreviouscaseseries.5,19,20
A pilot trial, conducted as a precursor to this trial, with 25mg
of weekly oral methotrexate but a lower dose of daily myco-
phenolatemofetil (2gdaily) foundconsistent results to thecur-
rent finding. In this trial, the standard maximum doses for
methotrexate and mycophenolate mofetil were compared.
Evenwith thesehighdoses, fewpatients’ treatment faileddue
to intolerability. The higher dose ofmethotrexate used in this
trial comparedwith previous retrospective studies on uveitis
may have contributed to the finding that mycophenolate
mofetil was not superior. It is possible that using 25 mg of
methotrexate subcutaneouslymay result in evengreater uve-
itis control given the increased bioavailability with subcuta-
neous administration.27
Table 3. Six-Month Adverse Events From a Randomized Clinical Trial ComparingMethotrexate
andMycophenolateMofetil for Noninfectious Uveitis
Event Typea
No. (%) of Patients Reporting ≥1 Adverse Event
Methotrexate
(n = 107)
Mycophenolate Mofetil
(n = 109)b
Nonserious ocular
Ocular hypertension >24 mm Hg 10 (9.3) 13 (12.0)
Peripheral and/or central vitreous hemorrhage 3 (2.8) 3 (2.8)
Suspect or confirmed glaucoma diagnosis 2 (1.9) 2 (1.9)
Intraocular pressure <5 mm Hg without structural damage 0 1 (0.9)
Visually significant cataract, surgery indicated 5 (4.7) 2 (1.9)
Decrease in vision or defective vision (self-reported) 9 (8.4) 19 (17.6)
Eye pain (self-reported) 9 (8.4) 4 (3.7)
Serious ocular
Glaucoma 0 1 (0.9)
Retinal detachment 1 (0.9) 0
Nonserious laboratory
Elevated ALT or AST (2 to 5 times upper limit of normal <28 d) 14 (13.0) 8 (7.4)
Low hemoglobin (>6.5 to <9 g/dL lasting <28 d) 2 (1.9) 3 (2.8)
Low leukocyte count (>1000 and <2500/μL lasting <28 d) 3 (2.8) 1 (0.9)
Elevated creatinine (>1.5 to <2 mg/dL lasting <28 d) 1 (0.9) 0
Serious laboratory
Extremely elevated ALT or AST (>5 times the upper limit of normal
or 2 to 5 times the upper limit of normal ≥28 d)c 3 (2.8) 2 (1.9)
Nonserious systemic
Fatigue 62 (57.9) 59 (54.6)
Headache 55 (51.4) 45 (41.7)
Mood changes (self-reported, not requiring therapy) 33 (30.8) 26 (24.1)
Hair loss 6 (5.6) 2 (1.9)
Nausea 42 (39.3) 30 (27.8)
Muscle weakness, no decrease in function 32 (29.9) 26 (24.1)
Numbness or tingling 25 (23.4) 18 (16.7)
Diarrhea 25 (23.4) 24 (22.2)
Dyspnea 21 (19.6) 22 (20.4)
Vomiting 26 (24.3) 24 (22.2)
Allergic reaction 14 (13.1) 11 (10.2)
Fever <39°C for 12 h 11 (10.3) 18 (16.7)
Mild congestive heart failure or arrhythmia not requiring therapy 4 (3.7) 2 (1.9)
Systemic infection 25 (23.4) 27 (25.0)
Other systemic (no treatment required) 65 (60.7) 63 (58.3)
Serious systemic
Death 1 (0.9) 0
Diarrhea 0 1 (0.9)
Disability or permanent damage 1 (0.9) 0
Hospitalization 2 (1.9) 2 (1.9)
Serious systemic infection 0 1 (0.9)
Vomiting 1 (0.9) 0
Other serious eventd 3 (2.8) 1 (0.9)
Abbreviations: ALT, alanine
aminotransferase; AST, aspartate
aminotransferase.
SI conversion: for creatinine to
μmol/L, multiply by 88.4.
a Criteria for defining serious and
nonserious adverse events are
included in eTable 1 in Supplement 1.
bOne patient in themycophenolate
mofetil group never received
mycophenolate mofetil due to
medical contraindication discovered
postrandomization.
c All drug-related serious adverse
events were due to extremely
elevated ALT, AST, or both in some
patients.
d Indicates stroke, injury to finger, and
lower limb pain within the
methotrexate group and extreme
flank pain within the
mycophenolate mofetil group.
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In rheumatology,disease-specific treatmentguidelinesex-
ist. For example, methotrexate is the preferred initial treat-
ment for rheumatoid arthritis and mycophenolate mofetil for
lupusnephritis.28-30Comparative trials are important toevalu-
ate the relativeefficacyof available treatmentoptions, and this
has been lacking for uveitis. The findings of this trial have im-
plications for clinical practice because they provide scientific
justification that mycophenolate mofetil is not more effective
thanmethotrexateasacorticosteroid-sparing immunosuppres-
sivetherapyforuveitis.Patientswithposterioruveitisandpanu-
veitis havemore vision complications thanother types of uve-
itis and often have chronic inflammation requiring long-term
immunosuppressive therapy.20,21 Methotrexate may be an ef-
fective, reasonable, first-line choice for these patients.
The strengths of this study include its randomizeddesign,
a large and geographically diverse patient population that in-
creasesgeneralizability, standardized treatment, andthemask-
ing of graders to reduce bias. The definition of treatment suc-
cess in this trialwas a clinically relevant composite outcomeof
assessing inflammation in all parts of both eyes and incorpo-
rating tolerability and safety. Many uveitis trials have focused
on only 1 aspect of inflammation, yet in clinical practice, treat-
ment is not adequate if it does not control inflammation in all
parts of the eye and corticosteroids cannot be tapered.
Limitations
Thisstudyhasseveral limitations.First,patientswerenotmasked
to theirmedication.However, studypersonnel responsible for
measuringoutcomesweremasked through 12months, includ-
ingwhen patients switchedmedication. Themasking of grad-
ers,alongwithusinghighlyreproduciblegradingscales,mitigated
the limitation of subjective inflammation grading for the defi-
nitionof treatment success.31 Second,patientswithaheteroge-
neousgroupofuveitis etiologieswere included to facilitate en-
rollment.Adifference intreatmenteffectbetweenintermediate
uveitis vsposterioruveitis andpanuveitiswas found,but there
wasnot sufficient statisticalpower tocomparebetweenuveitis
diagnoses.Third,mostpatientswereenrolled inIndia,but those
results did not drive the primary outcome.
Conclusions
Amongadultswithnoninfectiousuveitis, theuseofmycophe-
nolate mofetil compared with methotrexate as first-line
corticosteroid-sparing treatmentdidnot result in superior con-
trol of inflammation. Further research is needed to determine
if eitherdrug ismoreeffectivebasedontheanatomical subtype
of uveitis.
ARTICLE INFORMATION
Accepted for Publication: August 2, 2019.
Author Affiliations:Uvea Services, Aravind Eye
Hospitals and Postgraduate Institute of
Ophthalmology, Madurai, India (Rathinam,
Thundikandy, Vedhanayaki); F. I. Proctor
Foundation, University of California, San Francisco
(Gonzales, Doan, Keenan, Rao, Ebert, Nguyen, Kim,
Porco, Acharya); Department of Ophthalmology,
University of California, San Francisco (Gonzales,
Doan, Keenan, Porco, Acharya); Uvea Services,
Aravind Eye Hospitals and Postgraduate Institute of
Ophthalmology, Coimbatore, India (Kanakath);
Uvea Services, Aravind Eye Hospitals and
Postgraduate Institute of Ophthalmology,
Pondicherry, India (Murugan); Centre for Eye
Research Australia, Royal Victorian Eye and Ear
Hospital, East Melbourne, Australia (Lim); Casey
Eye Institute, Portland, Oregon (Suhler); Oregon
Health and Science University, Portland (Suhler);
OHSU-PSU School of Public Health, and VA
Portland Health Care System, Portland, Oregon
(Suhler); Division of Vitreoretinal Surgery and
Uveitis, King Khaled Eye Specialist Hospital, Riyadh,
Kingdom of Saudi Arabia (Al-Dhibi); Department of
Epidemiology and Biostatistics, University of
California, San Francisco (Porco, Acharya).
Author Contributions:Dr Porco andMr Kim had
full access to all of the data in the study and take
responsibility for the integrity of the data and the
accuracy of the data analysis.
Concept and design: Gonzales, Kanakath, Suhler,
Al-Dhibi, Acharya.
Acquisition, analysis, or interpretation of data: All
authors.
Drafting of the manuscript: Gonzales, Kanakath,
Bala Murugan, Vedhanayaki, Al-Dhibi, Rao, Ebert,
Nguyen, Porco, Acharya.
Critical revision of the manuscript for important
intellectual content: Rathinam, Gonzales,
Thundikandy, Kanakath, BalaMurugan, Lim, Suhler,
Al-Dhibi, Doan,Keenan, Ebert,Nguyen,Kim,Acharya.
Statisticalanalysis:Gonzales,Ebert,Nguyen,Kim,Porco.
Obtained funding: Acharya.
Administrative, technical,ormaterialsupport:Gonzales,
Kanakath, Bala Murugan, Vedhanayaki, Lim, Suhler,
Al-Dhibi, Keenan, Rao, Ebert,Nguyen,Acharya.
Supervision: Rathinam, Bala Murugan, Suhler,
Al-Dhibi, Acharya.
Conflict of InterestDisclosures:DrRathinam
reports receipt of grants fromAravind EyeHospital
during the conduct of the study. Dr Lim reports
receipt of grants from theNational Eye Institute (NEI)
during the conduct of the study; personal fees from
Allergan, Novartis, andNovotech; and grants and
personal fees fromAbbVie andBayer outside the
submittedwork. Dr Al-Dhibi reports receipt of
personal fees fromAbbVie, Allergan, andNovartis
(consultancies) outside the submittedwork. Dr Porco
reports receipt of grants fromNEI during the conduct
of the study. Dr Acharya reports receipt of grants
fromNEI during the conduct of the study and
personal fees fromSanten andAbbVie (consultancies
for advisory board participation) outside the
submittedwork. Dr Suhler reports receipt of personal
fees fromAbbVie, Clearside, EyeGate, EyePoint,
Gilead, Santen, and Eyevensys and grants from
AbbVie, Aldeyra, Clearside, EyeGate, EyePoint,
Genentech, andGilead. Drs Gonzales, Doan, and
Keenan report receipt of grant funding from theNEI.
No other disclosureswere reported.
Funding/Support: This study was supported by
NEI cooperative agreement U10 EY021125
(to Dr Acharya, primary investigator). The
University of California San Francisco pharmacy
provided study drugs for all sites. The Department
of Ophthalmology at UCSF is supported by an
unrestricted grant from the Research to Prevent
Blindness Foundation, a core grant (EY06190) from
the NEI, and That ManMay See Foundation.
Role of Funder/Sponsor: The National Institutes of
Health (NIH) did not have any direct role in the
design and conduct of the study; collection,
management, analysis, and interpretation of the
data; preparation of themanuscript; and decision
to submit themanuscript for publication. The data
and safety monitoring committee, appointed by the
NIH, reviewed and approved submitting this
manuscript for publication.
Group Information for the FASTResearch Group:
Aravind EyeHospital,Madurai, India: S. R. Rathinam,
MD, PhD (director); Radhika Thundikandy,MD; R.
Vedhanayaki,MD; A. L. Sivarama Subramanian,MPT;
G. Jeyakohila, DONA; Gracy Evangelin, BA; A.M.
Azhagupandi, HSC; C. V. Praba, HSC; S. Bharati, BSc;
P. Gomathi, SSC; N. J. Nirmaladevi, HSC;Mohammed
Siddiq; B. Vijayakumar; S. R. Devi. Aravind Eye
Hospital, Coimbatore, India: Anuradha Kanakath,MD
(director); V. R. Saravanan,MD;Upendra Babu,MD;
R. Srija,MSc; S. Dhanalakshmi, BA; R. R. Sakthimari,
COT; P. S. Keerthana, COT; A.M.Mallika, COT; C.
Vasanthi, COT; P. B.Mariselvi, COT; P. Pandeeswari; S.
M. Sudarvanitha, COT; S. Prema, COT. Aravind Eye
Hospital, Pondicherry, India: S. BalaMurugan,MD
(director); PrabuBaskaran,MD; V. G.
Madanagopalan,MD; K. Chokkahalli; K. Nagesha,MD;
R. Thilagavathi,MCom, E. S. Chitra, COT; S.M.
Krishnakumari, COT; P. Irudhaya Raj, COT; S.
Saravanan, BA; GraceMary, COT; K. Nagarasi, COT;
KirubaGnansi, COT. Asociación Para Evitar la Ceguera,
Mexico City,Mexico: Lourdes Arellanes-Garcia,MD
(director); Luz Elena Concha del Rio,MD; Rashel
Cheja Kalb,MD;Nancy Fernández,MD; YokoBurgoa,
BS; HildaHernández; Roberto Fabela Cuello, OD;
LorenzoAgustín, OD;MartínezGarcia; Ricardo
Montoya Rodríguez;Maria del CarmenPreciado, PhD;
Andrea Arreola,MD. King Khaled Eye Specialist
Hospital, Riyadh, Saudi Arabia: HassanA. Al-Dhibi,
MD (director); Donald Stone,MD;Mohammed
Al-Shamrani,MD; Sara Al-Nuwaysir, BSc;
AbdulrahmanAl-Hommadi, BBA; Abdullah
Research Original Investigation Corticosteroid-Sparing TreatmentWith Mycophenolate Mofetil vs Methotrexate in Patients With Uveitis
944 JAMA September 10, 2019 Volume 322, Number 10 (Reprinted) jama.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a UCSF LIBRARY User  on 09/18/2019
Al-Omran, BSc; Saleh Al-Nasser, BSc; Gahram
Al-Zahrani, BSc; EmanMashan, BSc;Mizher
Al-Ghamdi, BSc; AyshahAl-Tuwejri, BSc.
NorthwesternUniversity, Chicago, Illinois: Debra A.
Goldstein,MD (director); Anna Liza Castro-Malek,
MS; GemmaDela Rosa, COT;Marriner Skelly, BA, BS.
OregonHealth and ScienceUniversity, Portland: Eric
Suhler,MD,MPH (director); James Rosenbaum,MD;
Phoebe Lin,MD, PhD; Sherveen Salek,MD; Kristin
Biggee,MD; Amde Shifera,MD, PhD; Laura Kopplin,
MD, PhD; GeorgeMount,MD; TracyGiles, BS; Susan
Nolte; Ann Lundquist, BA, CCRP; Teresa Liesegang,
COT; Albert Romo; Chris Howell, BA; Scott Pickell, BS;
Peter Steinkemp,MS; DawnRyan, CRA; JordanBarth,
AAS; JocelynHui, BS; Chiedozie Ukachukwu, BS.
Royal Victorian Eye and EarHospital, EastMelbourne,
Australia: Lyndell Lim,MD (director); Richard Stawell,
MD; Robyn Troutbeck,MD; Cecilia Ling,MD; Xavier
Fagan,MD; Julian Bosco,MD; TimothyGodfrey,MD;
Tanya Pejnovic, BAppSc; Carly D’Sylva,MPH; Sutha
Sanmugasundram, BSc; Tina-Marie van Tonder;Maria
Kolic, BOOS. University of California, San Francisco:
Nisha Acharya,MD,MS (director); JohnGonzales,
MD; ThuyDoan,MD, PhD; Sarah Lopez, OD;Maya
Rao,MPH; Erica Browne,MS; BettyHom, BS;Mary
Lew, COT; Salena Lee, OD. The remaining
acknowledgements list indviduals at FASTResearch
GroupResource Centers. Coordinating Center,
University of California, San Francisco, CA: Nisha
Acharya,MD,MS; Travis Porco, PhD,MPH; Thomas
Lietman,MD; JeremyKeenan,MD,MPH; Eric Kim,
MA;HieuNguyen,MS; Caleb Ebert,MPH; former
members:Maya Rao,MPH; Elyse Berlinberg, BS; Erica
Browne,MS; AndrewHirst,MS; RachelWeinrib,MPH.
Data and SafetyMonitoring Committee Voting
Members:MaureenG.Maguire, PhD (chair);William
E. Barlow, PhD; Steven Yeh,MD; Albert T. Vitale,MD;
Jaqueline J. Glover, PhD;Narsing A. Rao,MD; former
member: Debra A. Goldstein,MD.NEI Program
Office: Donald F. Everett,MA. University of South
Florida Fundus Photograph andOCTReading Center,
Tampa, Florida: Peter R. Pavan,MD (director); JoAnn
Leto; former director: BrianMadow,MD.
Additional Information: The data and safety
monitoring committee monitored efficacy, safety,
and overall study performance throughout the trial.
Data Sharing Statement: See Supplement 4.
REFERENCES
1. Gritz DC, Wong IG. Incidence and prevalence of
uveitis in Northern California; the Northern
California Epidemiology of Uveitis Study.
Ophthalmology. 2004;111(3):491-500. doi:10.1016/j.
ophtha.2003.06.014
2. Suttorp-SchultenMS, Rothova A. The possible
impact of uveitis in blindness: a literature survey. Br
J Ophthalmol. 1996;80(9):844-848. doi:10.1136/
bjo.80.9.844
3. Rosenbaum JT, Dick AD. The eyes have it:
a rheumatologist’s view of uveitis. Arthritis
Rheumatol. 2018;70(10):1533-1543. doi:10.1002/art.
40568
4. Jabs DA, Rosenbaum JT, Foster CS, et al.
Guidelines for the use of immunosuppressive drugs
in patients with ocular inflammatory disorders:
recommendations of an expert panel. Am J
Ophthalmol. 2000;130(4):492-513. doi:10.1016/
S0002-9394(00)00659-0
5. Galor A, Jabs DA, Leder HA, et al. Comparison of
antimetabolite drugs as corticosteroid-sparing
therapy for noninfectious ocular inflammation.
Ophthalmology. 2008;115(10):1826-1832. doi:10.
1016/j.ophtha.2008.04.026
6. Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab
in patients with active noninfectious uveitis.N Engl
J Med. 2016;375(10):932-943. doi:10.1056/
NEJMoa1509852
7. Dick AD, Rosenbaum JT, Al-Dhibi HA, et al;
Fundamentals of Care for Uveitis International
Consensus Group. Guidance on noncorticosteroid
systemic immunomodulatory therapy in
noninfectious uveitis: Fundamentals Of Care for
Uveitis (FOCUS) initiative.Ophthalmology. 2018;125
(5):757-773. doi:10.1016/j.ophtha.2017.11.017
8. Teoh SC, Hogan AC, Dick AD, Lee RWJ.
Mycophenolate mofetil for the treatment of uveitis.
Am J Ophthalmol. 2008;146(5):752-760, 760.e1-
760.e3. doi:10.1016/j.ajo.2008.03.004
9. Thorne JE, Jabs DA, Qazi FA, Nguyen QD,
Kempen JH, Dunn JP. Mycophenolate mofetil
therapy for inflammatory eye disease.
Ophthalmology. 2005;112(8):1472-1477. doi:10.1016/
j.ophtha.2005.02.020
10. Baltatzis S, Tufail F, Yu EN, Vredeveld CM,
Foster CS. Mycophenolate mofetil as an
immunomodulatory agent in the treatment of
chronic ocular inflammatory disorders.
Ophthalmology. 2003;110(5):1061-1065. doi:10.1016/
S0161-6420(03)00092-7
11. Gangaputra S, Newcomb CW, Liesegang TL,
et al; Systemic Immunosuppressive Therapy for Eye
Diseases Cohort Study. Methotrexate for ocular
inflammatory diseases.Ophthalmology. 2009;116
(11):2188-98.e1. doi:10.1016/j.ophtha.2009.04.020
12. Sobrin L, ChristenW, Foster CS. Mycophenolate
mofetil after methotrexate failure or intolerance in
the treatment of scleritis and uveitis.Ophthalmology.
2008;115(8):1416-1421, 1421.e1. doi:10.1016/j.ophtha.
2007.12.011
13. National Institutes of Health. NIH policy and
guidelines on the inclusion of women and
minorities as subjects in clinical research. https://
grants.nih.gov/policy/inclusion/women-and-
minorities/guidelines.htm. Accessed June 24, 2019.
14. US Food and Drug Administration (FDA).
Collection of race and ethnicity data in clinical trials.
https://www.fda.gov/regulatory-information/
search-fda-guidance-documents/collection-race-
and-ethnicity-data-clinical-trials?source=
govdelivery&utm_medium=email&utm_source=
govdelivery. Published 2016. Accessed June 24, 2019.
15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez
N, Conde JG. Research electronic data capture
(REDCap)—ametadata-drivenmethodology and
workflow process for providing translational
research informatics support. J Biomed Inform.
2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010
16. Jabs DA, Nussenblatt RB, Rosenbaum JT;
Standardization of Uveitis Nomenclature (SUN)
Working Group. Standardization of uveitis
nomenclature for reporting clinical data: results of
the first international workshop. Am J Ophthalmol.
2005;140(3):509-516. doi:10.1016/j.ajo.2005.03.057
17. Daniel E, Thorne JE, Newcomb CW, et al.
Mycophenolate mofetil for ocular inflammation. Am
J Ophthalmol. 2010;149(3):423-32.e1, 2. doi:10.
1016/j.ajo.2009.09.026
18. Fleiss JL, Levin B, Paik MC. 6.9 Standard errors
for measures of association. In: Balding DJ, Cressie
NAC, Fisher NI, et al, eds. Statistical Methods for
Rates and Proportions. 3rd ed. Hoboken, NJ: John
Wiley & Sons; 2003.
19. Rathinam SR, BabuM, Thundikandy R, et al.
A randomized clinical trial comparing methotrexate
andmycophenolate mofetil for noninfectious
uveitis.Ophthalmology. 2014;121(10):1863-1870.
doi:10.1016/j.ophtha.2014.04.023
20. Kempen JH, Van Natta ML, Altaweel MM, et al;
Multicenter Uveitis Steroid Treatment (MUST) Trial
Research Group. Factors predicting visual acuity
outcome in intermediate, posterior, and panuveitis:
the Multicenter Uveitis Steroid Treatment (MUST)
trial. Am J Ophthalmol. 2015;160(6):1133-1141.e9.
doi:10.1016/j.ajo.2015.09.017
21. Jabs DA. Immunosuppression for the uveitides.
Ophthalmology. 2018;125(2):193-202. doi:10.1016/j.
ophtha.2017.08.007
22. Foeldvari I, Wierk A. Methotrexate is an
effective treatment for chronic uveitis associated
with juvenile idiopathic arthritis. J Rheumatol.
2005;32(2):362-365.
23. Bom S, Zamiri P, Lightman S. Use of
methotrexate in themanagement of
sight-threatening uveitis.Ocul Immunol Inflamm.
2001;9(1):35-40. doi:10.1076/ocii.9.1.35.3983
24. Dev S, McCallum RM, Jaffe GJ. Methotrexate
treatment for sarcoid-associated panuveitis.
Ophthalmology. 1999;106(1):111-118. doi:10.1016/
S0161-6420(99)90011-8
25. Holz FG, Krastel H, Breitbart A, Schwarz-Eywill
M, Pezzutto A, Völcker HE. Low-dosemethotrexate
treatment in noninfectious uveitis resistant to
corticosteroids. Ger J Ophthalmol. 1992;1(3-4):142-
144.
26. Shah SS, Lowder CY, Schmitt MA,WilkeWS,
Kosmorsky GS, Meisler DM. Low-dose
methotrexate therapy for ocular inflammatory
disease.Ophthalmology. 1992;99(9):1419-1423.
doi:10.1016/S0161-6420(92)31790-7
27. Schiff MH, Jaffe JS, Freundlich B.
Head-to-head, randomised, crossover study of oral
versus subcutaneous methotrexate in patients with
rheumatoid arthritis: drug-exposure limitations of
oral methotrexate at doses15 mgmay be
overcomewith subcutaneous administration. Ann
RheumDis. 2014;73(8):1549-1551. doi:10.1136/
annrheumdis-2014-205228
28. Dooley MA, Jayne D, Ginzler EM, et al; ALMS
Group. Mycophenolate versus azathioprine as
maintenance therapy for lupus nephritis.N Engl J
Med. 2011;365(20):1886-1895. doi:10.1056/
NEJMoa1014460
29. Smolen JS, Landewé R, Bijlsma J, et al. EULAR
recommendations for themanagement of
rheumatoid arthritis with synthetic and biological
disease-modifying antirheumatic drugs: 2016
update. Ann RheumDis. 2017;76(6):960-977. doi:
10.1136/annrheumdis-2016-210715
30. Singh JA, Saag KG, Bridges SL Jr, et al;
American College of Rheumatology. 2015 American
College of Rheumatology guideline for the
treatment of rheumatoid arthritis. Arthritis Care Res
(Hoboken). 2016;68(1):1-25. doi:10.1002/acr.22783
31. Kempen JH, Ganesh SK, Sangwan VS, Rathinam
SR. Interobserver agreement in grading activity and
site of inflammation in eyes of patients with uveitis.
Am J Ophthalmol. 2008;146(6):813-8.e1. doi:10.
1016/j.ajo.2008.06.004
Corticosteroid-Sparing TreatmentWith Mycophenolate Mofetil vs Methotrexate in Patients With Uveitis Original Investigation Research
jama.com (Reprinted) JAMA September 10, 2019 Volume 322, Number 10 945
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a UCSF LIBRARY User  on 09/18/2019
